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Acute kidney injury increases mortality risk among those with
established chronic kidney disease. In this study we used a
propensity score-matched cohort method to retrospectively
evaluate the risks of death and de novo chronic kidney
disease after reversible, hospital-associated acute kidney
injury among patients with normal pre-hospitalization kidney
function. Of 30,207 discharged patients alive at 90 days,
1610 with reversible acute kidney injury that resolved within
the 90 days were successfully matched across multiple
parameters with 3652 control patients who had not
experienced acute kidney injury. Median follow-up was 3.3
and 3.4 years (injured and control groups, respectively).
In Cox proportional hazard models, the risk of death
associated with reversible acute kidney injury was significant
(hazard ratio 1.50); however, adjustment for the
development of chronic kidney injury during follow-up
attenuated this risk (hazard ratio 1.18). Reversible acute
kidney injury was associated with a significant risk of
de novo chronic kidney disease (hazard ratio 1.91). Thus,
a resolved episode of hospital-associated acute kidney injury
has important implications for the longitudinal surveillance
of patients without preexisting, clinically evident
kidney disease.
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Hospital-associated acute kidney injury (AKI) is common,
affecting up to 1% of the general population and 15% of all
hospitalized patients.1–4 In the United States alone, more than
3 million hospitalized individuals annually are at risk.5
AKI is not benign; the risk of in-hospital death after
such an event is increased 2.5-fold compared with similar
patients without AKI,6 and the long-term risk of death
is similarly increased for subpopulations of patients with
preexisting chronic kidney disease (CKD).7 A causative
relationship between AKI and these long-term risks has not
been established, although it has been postulated that AKI
may result in a number of systemic vascular endothelial
alterations that impact cardiovascular health.8 Whether
reversible episodes of AKI represent a risk for long-term
mortality in patients without underlying CKD is unknown,
although these patients are not traditionally considered an
at-risk population.9
We hypothesized that reversible changes in kidney
function among hospitalized patients without preexisting,
clinically evident kidney disease would increase the long-
term risk of death and CKD. We assembled a cohort of
hospitalized adults without evidence of kidney disease before
admission, and who survived at least 90 days after discharge.
Patients were stratified by AKI status, matched across a broad
range of variables previously associated with AKI, and
followed for the outcomes of interest.
RESULTS
Of 39,477 individuals admitted to Geisinger Medical Center
between 1 January 2004 and 31 December 2007, 30,207
patients were alive 90 days after discharge. Of these, 10,179
met at least one exclusion criterion or failed to recover kidney
function after AKI. Of the remaining 20,028 individuals, 1997
met criteria for recovered AKI; 18,031 patients not experi-
encing AKI served as potential controls. Of the 1997 with
recovered AKI, 1610 (80.6%) were successfully matched with
up to 3 (n¼ 3652) controls using a 5-1 digit ‘greedy’ match
algorithm. This served as the final study cohort.
The baseline characteristics of the two groups prior to
propensity score matching are shown in Table 1. In brief,
compared with controls, patients who developed AKI were
older, had more comorbid conditions, lower serum albumin
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levels, longer index hospitalizations, and a higher utilization
of critical care services during the hospital stay. In all, 1137
(70.6%), 363 (22.6%), and 106 (6.6%) subjects met the Acute
Kidney Injury Network stages 1, 2, and 3 criteria, respectively;
only 4 subjects required temporary renal replacement
therapy. Of these four, none died but two subsequently
developed CKD after recovery. The duration of AKI was 24 h
or less in 75% of patients, and between 2 and 4 days in
16.3%; only in 8.6% of patients did AKI fail to resolve
within 4 days. Mean (s.d.) recovery estimated glomerular
filtration rate (eGFR) for patients in the AKI group was
98.5 (22.0) ml/min per 1.73 m2.
The matching process resulted in a final cohort that
excluded those AKI cases with a greater underlying disease
burden and more severe acute illness relative to those AKI
cases matched with controls, as can be seen in Table 2.
Characteristics of the propensity score–matched groups
are shown in Table 3. After matching, the groups were
Table 1 | Baseline characteristics of hospitalized patients (2004–2007) surviving at least 90 days after discharge, by AKI status,
and before matching for the propensity to develop AKI
AKI group
(n=1997)
Control group
(n=18,031) P-valuea
Demographic characteristic
Age, years; median (IQR) 64.0 (53.0, 74.0) 59.0 (46.0, 71.0) o0.0001
Male, n (%) 951 (47.6) 8033 (44.6) 0.009
White, n (%) 1959 (98.1) 17,688 (98.1) 0.89
Smoking history, n (%) 3128 (15.9) 3000 (16.6) 0.42
Characteristics of index hospitalization
Length of hospitalization, days; median (IQR) 6.0 (3.0, 12.0) 2.0 (0.0, 3.0) o0.0001
Received critical care, n (%) 359 (18.0) 416 (2.3) o0.0001
Inpatient serum albumin (value closest to hospital discharge), mg/dl; median (IQR)a 3.3 (2.9, 3.8) 3.9 (3.5, 4.2) o0.0001
Clinical characteristic
Baseline eGFR, ml/min per 1.73m2; median (IQR) 97.8 (86.8, 110.8) 96.3 (85.0, 108.5) o0.0001
Outpatient serum albumin (value closest to index admission date), mg/dl; median (IQR)b 3.9 (3.5, 4.2) 4.2 (3.9, 4.4) o0.0001
Diabetes, n (%) 598 (29.9) 3592 (19.9) o0.0001
Hypertension, n (%) 1174 (58.8) 7988 (44.3) o0.0001
Congestive heart failure, n (%) 203 (10.2) 678 (3.8) o0.0001
Atherosclerotic coronary artery disease, n (%) 485 (24.3) 2742 (15.2) o0.0001
Cardiac dysrhythmias, n (%) 291 (14.6) 1273 (7.1) o0.0001
Peripheral vascular disease, n (%) 117 (5.9) 510 (2.8) o0.0001
Stroke, n (%) 192 (9.6) 998 (5.5) o0.0001
Cancer, n (%) 377 (18.9) 1770 (9.8) o0.0001
Dementia, n (%) 29 (1.4) 157 (0.9) 0.01
Liver diseasec, n (%) 38 (1.9) 194 (1.1) 0.001
Chronic lung diseased, n (%) 366 (18.3) 2344 (13.0) o0.0001
Obesity, n (%) 185 (9.3) 1325 (7.4) 0.002
Major infectione, n (%) 153 (7.7) 602 (3.3) o0.0001
Renal/cardiovascular medicationf, n (%) 1033 (51.7) 8267 (45.8) o0.0001
Charlson Co-morbidity Index Score, n (%) o0.0001
0 723 (36.2) 10,110 (56.1)
1 532 (26.6) 4508 (25.0)
2+ 742 (37.2) 3413 (18.9)
Procedure
Single 12-lead or 24-h electrocardiography, n (%) 1673 (83.8) 10,979 (60.9) o0.0001
Echocardiography, n (%) 644 (32.2) 3242 (18.0) o0.0001
Cardiac stress testing, n (%) 164 (8.2) 1476 (8.2) 0.97
Angiography (coronary, peripheral arterial), n (%) 241 (12.1) 1646 (9.1) o0.0001
Surgical revascularization (coronary, carotid, aortic, and peripheral arterial), n (%) 130 (6.5) 432 (2.4) o0.0001
Cardiac valvular surgery, n (%) 71 (3.6) 98 (0.5) o0.0001
Abbreviations: AKI, hospital-associated acute kidney injury; CPT, Current Procedural Terminology; eGFR, estimated glomerular filtration rate; IQR, interquartile range.
aData available for 1308 (65.5%) patients in AKI group and 3498 (19.4%) controls.
bData available for 1592 (79.7%) patients in AKI group and 10,686 (59.3%) controls.
cChronic hepatitis, alcoholic fatty liver, hepatorenal syndrome, portosystemic encephalopathy, spontaneous bacterial peritonitis, esophageal varices.
dAsthma, emphysema, and chronic bronchitis.
eSepsis and septicemia, intra-abdominal infections, central nervous system infections, acute and subacute endocarditis, community acquired, nosocomial, bacterial, fungal,
and viral pneumonias, pyelonephritis and perinephric abscess, skin and soft tissue infections.
fPrescription order for any one of the following during the 6 months before index admission date: angiotensin-converting enzyme inhibitor, angiotensin receptor blocker,
b-blocker, calcium channel blocker, loop or thiazide diuretic, aldosterone antagonist, oral anticoagulant, antiplatelet agent, hydroxy-methyl–glutaryl coenzyme A reductase
inhibitor, nonsteroidal anti-inflammatory agent, erythropoietin-stimulating agent, or one of the following antibiotic classes: penicillins, cephalosporins, aminoglycosides.
See Supplementary Appendix online for a comprehensive list of ICD-9-CM and CPT codes, and operational definitions, for the covariates listed.
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balanced across all variables but length of hospitalization.
The mean age was 61 years; 47% of matched individuals were
men and 15% were smokers. A substantial proportion (22%)
had diabetes and/or cardiovascular disease. In all, 6% had
major infections in the year before index hospitalization.
Almost 10% of the matched cohort required critical care
services during hospitalization.
During a median (interquartile range) follow-up of 3.3
(2.4, 4.3) years in the AKI group and 3.4 (2.6, 4.3) years in the
control group, there were 144 deaths among patients with AKI
and 233 deaths among controls (Figure 1). The mortality rate
during this period was significantly higher in the AKI group,
compared with patients without AKI: 2.8 vs. 1.9 deaths/1000
person years, respectively; mortality rate ratio (95% con-
fidence interval (CI)) was 1.48 (1.20, 1.83, P¼ 0.0002).
CKD developed in 841 patients in the AKI group and 1218
patients in the control group. The median (interquartile
range) time to CKD in those experiencing AKI was 31 (2,
200) days, as compared with 140 (24, 380) days for those not
experiencing AKI (Figure 2). The incident rates for CKD were
Table 2 | Baseline characteristics of hospitalized patients (2004–2007) with reversible AKI surviving at least 90 days after
discharge, by match status
Matched AKI
(n=1610)
Unmatched AKI
(n=387) P-valuea
Demographic characteristic
Age, years; median (IQR) 63.0 (52.0, 74.0) 67.0 (56.0, 75.0) 0.0003
Male, n (%) 753 (46.8) 198 (51.2) 0.12
White, n (%) 1582 (98.3) 377 (97.4) 0.27
Smoking history, n (%) 249 (15.5) 69 (17.8) 0.25
Characteristics of index hospitalization
Length of hospitalization, days; median (IQR) 5.0 (3.0, 8.0) 16.0 (10.0, 26.0) o0.0001
Received critical care, n (%) 156 (9.7) 203 (52.4) o0.0001
Inpatient serum albumin (value closest to hospital discharge), mg/dl; median (IQR)a 3.5 (3.0, 3.9) 3.0 (2.6, 3.4) o0.0001
Clinical characteristic
Baseline eGFR, ml/min per 1.73m2; median (IQR) 97.2 (86.4, 110.0) 100.1 (88.8, 115.3) 0.001
Outpatient serum albumin (value closest to index admission date), mg/dl; median (IQR)b 3.9 (3.6, 4.3) 3.7 (3.1, 4.1) o0.0001
Diabetes, n (%) 466 (28.9) 132 (34.1) 0.046
Hypertension, n (%) 929 (57.7) 245 (63.3) 0.044
Congestive heart failure, n (%) 138 (8.6) 65 (16.8) o0.0001
Atherosclerotic coronary artery disease, n (%) 366 (22.7) 119 (30.8) 0.0009
Cardiac dysrhythmias, n (%) 197 (12.2) 94 (24.3) o0.0001
Peripheral vascular disease, n (%) 82 (5.1) 35 (9.0) 0.003
Stroke, n (%) 134 (8.3) 58 (15.0) o0.0001
Cancer, n (%) 284 (17.6) 93 (24.0) 0.0039
Dementia, n (%) 19 (1.2) 10 (2.6) 0.038
Liver diseasec, n (%) 31 (1.9) 7 (1.8) 0.88
Chronic lung diseased, n (%) 274 (17.0) 92 (23.8) 0.002
Obesity, n (%) 154 (9.6) 31 (8.0) 0.34
Major infectione, n (%) 105 (6.5) 48 (12.4) o0.0001
Renal/cardiovascular medicationf, n (%) 815 (50.6) 218 (56.3) 0.043
Charlson Co-morbidity Index Score, n (%) o0.0001
0 606 (37.6) 117 (30.2)
1 444 (27.6) 88 (22.7)
2+ 560 (34.8) 182 (47.0)
Procedure
Single 12-lead or 24-h electrocardiography, n (%) 1321 (82.0) 352 (91.0) o0.0001
Echocardiography, n (%) 506 (31.4) 138 (35.7) 0.11
Cardiac stress testing, n (%) 136 (8.5) 28 (7.2) 0.44
Angiography (coronary, peripheral arterial), n (%) 201 (12.5) 40 (10.3) 0.24
Surgical revascularization (coronary, carotid, aortic, and peripheral arterial), n (%) 90 (5.6) 40 (10.3) 0.0007
Abbreviations: AKI, hospital-associated acute kidney injury; eGFR, estimated glomerular filtration rate; IQR, interquartile range.
aData available for 941 (58.4%) patients in matched group and 367 (94.8%) unmatched.
bData available for 1261 (78.3%) patients in matched group and 331 (85.5%) unmatched.
cChronic hepatitis, alcoholic fatty liver, hepatorenal syndrome, portosystemic encephalopathy, spontaneous bacterial peritonitis, esophageal varices.
dAsthma, emphysema, and chronic bronchitis.
eSepsis and septicemia, intra-abdominal infections, central nervous system infections, acute and subacute endocarditis, community acquired, nosocomial, bacterial, fungal,
and viral pneumonias, pyelonephritis and perinephric abscess, skin and soft tissue infections.
fPrescription order for any one of the following during the 6 months before index admission date: angiotensin-converting enzyme inhibitor, angiotensin receptor blocker,
b-blocker, calcium channel blocker, loop or thiazide diuretic, aldosterone antagonist, oral anticoagulant, antiplatelet agent, hydroxy-methyl–glutaryl coenzyme A reductase
inhibitor, nonsteroidal anti-inflammatory agent, erythropoietin-stimulating agent, or one of the following antibiotic classes: penicillins, cephalosporins, aminoglycosides.
See Supplementary Appendix online for a comprehensive list of ICD-9-CM and CPT codes, and operational definitions, for the covariates listed.
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28.1 and 13.1/1000 person years in the AKI and control
groups, respectively; the corresponding CKD rate ratio (95%
CI) was 2.14 (1.96, 2.43), Po0.0001.
In the Cox proportional hazard analysis for mortality,
adjusted for hospital length of stay, a reversible AKI event was
associated with a 50% higher risk of death (hazard ratios (HR)
1.50; 95% CI, 1.21, 1.85, P¼ 0.0002). The risk of de novo
CKD was increased nearly twofold (HR 1.91; 95% CI,
1.75–2.09, Po0.0001). Adjusting for the development of
CKD in the time-to-death analysis resulted in a substantial
attenuation of the long-term risk conferred by an episode of
reversible AKI. When incident CKD was added to the Cox
Table 3 | Characteristics of the hospitalized cohort with normal preadmission kidney function and alive 90 days after discharge,
matched for the propensity to develop AKI
AKI group
(n=1610)
Control group
(n=3652)
Absolute
standardized
difference
Demographic characteristic
Age, years; median (IQR) 63.0 (52.0, 74.0) 63.0 (51.0, 73.0) 4.8
Male, n (%) 753 (46.8) 1660 (45.4) 0.2
Whites, n (%) 1582 (98.3) 3592 (98.4) 0.01
Smoking history, n (%) 249 (15.5) 568 (15.6) 0.03
Characteristics of index hospitalization
Length of hospitalization, days; median (IQR) 5.0 (3.0, 8.0) 4.0 (3.0, 7.0) 19.6a
Received critical care, n (%) 156 (9.7) 267 (7.3) 0.8
Inpatient serum albumin (value closest to hospital discharge), mg/dl; median (IQR) 3.5 (3.0, 3.9) 3.8 (3.4, 4.1) 3.0
Clinical characteristic
Baseline eGFR, ml/min per 1.73m2; median (IQR) 97.2 (86.4, 110.0) 97.0 (86.1, 109.7) 2.4
Outpatient serum albumin value (value closest to index admission date),
mg/dl; median (IQR)b
3.9 (3.6, 4.3) 4.0 (3.6, 4.3) 5.3
Diabetes, n (%) 466 (28.9) 975 (26.7) 0.4
Hypertension, n (%) 929 (57.7) 2036 (55.8) 0.3
Congestive heart failure, n (%) 138 (8.6) 249 (6.8) 0.6
Atherosclerotic coronary artery disease, n (%) 366 (22.7) 780 (21.4) 0.3
Cardiac dysrhythmias, n (%) 197 (12.2) 394 (10.8) 0.4
Peripheral vascular disease, n (%) 82 (5.1) 172 (4.7) 0.2
Stroke, n (%) 134 (8.3) 283 (7.8) 0.2
Cancer, n (%) 284 (17.6) 564 (15.4) 0.5
Dementia, n (%) 19 (1.2) 39 (1.1) 0.1
Liver disease, n (%)c 31 (1.9) 45 (1.2) 0.6
Chronic lung disease, n (%)d 274 (17.0) 571 (15.6) 0.3
Obesity, n (%) 154 (9.6) 309 (8.5) 0.4
Major infection, n (%)e 105 (6.5) 214 (5.9) 0.2
Renal/cardiovascular medication, n (%)f 815 (50.6) 1846 (50.6) 0.0
Charlson Co-morbidity Index Score, n (%) 9.3
0 606 (37.6) 1056 (43.2)
1 444 (27.6) 1017 (27.8)
2+ 560 (34.8) 1056 (28.9)
Procedures
Single 12-lead or ambulatory 24-h electrocardiography, n (%) 1321 (82.0) 2953 (80.9) 0.1
Echocardiography, n (%) 506 (31.4) 1069 (29.3) 0.4
Cardiac stress testing, n (%) 136 (8.5) 319 (8.7) 0.1
Surgical revascularization (coronary, carotid, aortic, and peripheral arterial
and/or cardiac valvular surgery), n (%)g
90 (5.6) 181 (5.0) 0.3
Angiography (coronary and/or peripheral arterial), n (%) 201 (12.5) 473 (13.0) 0.1
Abbreviations: AKI, hospital-associated acute kidney injury; eGFR, estimated glomerular filtration rate; IQR, interquartile range.
aData available for 941 (58.5%) patients in AKI group and 1876 (51.4%) controls.
bData available for 1261 (78.3%) patients in AKI group and 2769 (75.8%) controls.
cChronic hepatitis, alcoholic fatty liver, hepatorenal syndrome, portosystemic encephalopathy, spontaneous bacterial peritonitis, esophageal varices.
dAsthma, emphysema, and chronic bronchitis.
eSepsis and septicemia, intra-abdominal infections, central nervous system infections, acute and subacute endocarditis, community acquired, nosocomial, bacterial, fungal,
and viral pneumonias, pyelonephritis and perinephric abscess, skin and soft tissue infections.
fPrescription order for any one of the following during the 6 months before index admission date: angiotensin-converting enzyme inhibitor, angiotensin receptor blocker,
b-blocker, calcium channel blocker, loop or thiazide diuretic, aldosterone antagonist, oral anticoagulant, antiplatelet agent, hydroxy-methyl–glutaryl coenzyme A reductase
inhibitor, nonsteroidal anti-inflammatory agent, erythropoietin-stimulating agent, or one of the following antibiotic classes: penicillins, cephalosporins, aminoglycosides.
gFor the purposes of propensity score matching, the categories of surgical revascularization and cardiac valve surgery were combined because of the infrequency of each
type of procedure.
See Supplementary Appendix online for a comprehensive list of ICD-9-CM and CPT codes, and operational definitions, for the covariates listed.
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model for mortality as a time-dependent covariate, the HR
(95% CI) for death associated with AKI was nonsignificant:
1.18 (0.95, 1.46; P¼ 0.13; Table 4). Further, within the sub-
group of patients who experienced AKI, those who subse-
quently developed CKD had a 3.6-fold increased incidence
of death compared with the group not developing CKD:
mortality rate ratio (95% CI) 3.65 (2.42, 5.52, Po0.0001;
Table 5). A sensitivity analysis was completed using the full,
unmatched cohort (n¼ 20,028). A multivariable Cox pro-
portional hazard regression model was fit, which included
all variables used in the propensity score model, as well as
the development of CKD during follow-up. The mortality
hazard associated with AKI in the multivariable regression
was consistent with that observed in the primary analysis
(HR¼ 1.15, 95% CI: 0.95, 1.39, P¼ 0.16). The results of the
sensitivity analyses for definitions of AKI based on the
baseline serum creatinine occurring 90 days before AKI or 30
days after AKI were similarly consistent with the primary
analysis (data not shown).
The association between AKI and mortality was consistent
in population subgroups (ageX65 years vs. younger, diabetic
status, requirement for critical care services, and Charlson
Co-morbidity Index score of X2, vs. 0 or 1). Figure 3 shows
the results of individual Cox proportional hazard survival
models for each subgroup of the final, matched cohort.
In each case, the model is adjusted for hospital length of stay,
as well as for the development of de novo CKD during follow-
up, in a time-dependent manner. Tests of interactions of
the each subgroup and the mortality outcome were not
significant (data not shown).
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Figure 1 |Unadjusted survival by exposure status (recovered
acute kidney injury (AKI) group vs. controls) among patients
with normal baseline kidney function.
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Figure 2 |Cumulative incidence of chronic kidney disease
(CKD) by exposure status (recovered acute kidney injury (AKI)
group vs. controls) among patients with normal baseline
kidney function.
Table 4 | Cox proportional hazard for time to death and
de novo CKD (recovered AKI vs. controls)
Death HR
(95% CI)
De novo
CKD HR (95% CI)
Adjusted for index hospital
length-of-stay
1.48 (1.19, 1.82)
P=0.0003
1.91 (1.75, 2.09)
Po0.0001
Adjusted for index hospital
length-of-stay and de novo CKD
1.18 (0.95, 1.46)
P=0.13
NA
Abbreviations: AKI, hospital-associated acute kidney injury; CI, confidence interval;
CKD, chronic kidney disease; HR, hazard ratio.
Table 5 |Mortality rates among long-term hospital survivors,
by AKIa and de novo CKD status
No AKI,
No CKD
(n=2434)
No AKI,
CKD
(n=1218)
AKI,
No CKD
(n=769)
AKI,
CKD
(n=841)
No. of deaths 102 131 28 116
Person years follow-up 8155.2 4287.4 2429.8 2756.0
Mortality rate, no. of
deaths/1000 person years
12.5 30.6 11.5 42.1
Abbreviations: AKI, hospital-associated acute kidney injury; CKD, chronic kidney
disease.
aPatients with and without AKI were matched across a broad range of covariates for
the propensity to develop AKI. All patients had no evidence of CKD at baseline;
‘CKD’ in this table refers to the development of CKD during follow-up after recovery
from AKI.
Diabetes - yes
Diabetes - no
Critical care - yes
Critical care - no
CCI -2
CCI -1
Age -65
Age - < 65
0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0
Hazard ratio
Figure 3 |Cox proportional hazard survival (recovered acute
kidney injury vs. controls) by cohort subgroups. These models
were developed for each specified subgroup from the final
matched cohort (n¼ 1610 and 3652 cases and controls,
respectively). Each model is adjusted for index hospital length
of stay, as well as for the development of chronic kidney disease
during follow-up, as in the primary analysis. CCI, Charlson
Co-morbidity Index.
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Predictors of de novo CKD among the matched AKI
subcohort are shown in Table 6. Older age and a history of
hypertension, congestive heart failure, and higher Charlson
score at the time of index admission all predicted subsequent
CKD, as did a longer index hospitalization and incremental
severity of AKI. Higher baseline serum albumin and eGFR
each were associated with a lower risk of de novo CKD during
longitudinal follow-up.
DISCUSSION
This study evaluated the long-term risks of death and de novo
CKD following reversible AKI among adults without
clinically evident renal disease both before and after the
insult. We found that despite fairly rapid recovery of renal
function, such episodes—involving largely modest increases
in serum creatinine—were associated with a 90% increased
risk of developing CKD during longitudinal follow-up. In
addition, whereas patients suffering from AKI were at higher
risk of death after recovery, the risk associated with the
AKI event was significantly attenuated after adjustment for
the development of subsequent CKD.
These results suggest that this population of patients
without apparent underlying renal disease—a group tradi-
tionally considered low risk—is nonetheless at risk for
clinically important long-term outcomes.10 In particular,
those who subsequently developed CKD in this cohort
after resolved AKI incurred substantial mortality risk. The
differential impact of AKI and CKD on mortality risk in our
cohort is highlighted by a comparison of mortality rates by
categories of AKI and CKD, as shown in Table 5. Despite
near-equivalent death rates for those matched patients with
and without AKI who do not subsequently develop CKD,
the more-than-threefold increased risk of death for those
matched patients with AKI who developed CKD relative to
the non-AKI controls who did not develop CKD is striking.
The observation that the mortality risk associated with AKI
in this population is largely attenuated by the development
of CKD is consistent with a large body of literature linking
CKD itself with an increased risk of death, relative to those
with normal kidney function.11–13
An association between AKI and long-term mortality has
previously been observed among patients with established
CKD, or in mixed populations with and without CKD. This
relationship appears to be consistent both among those with
more severe, dialysis-requiring AKI14,15 and those with less
severe cases of AKI.16–20 A recent meta-analysis of 48 studies
evaluating long-term outcomes after AKI determined that
AKI of any severity was associated with a doubling of long-
term mortality risk compared with individuals who have not
experienced AKI.7 In addition, an observational cohort of US
veterans with a low (4%) prevalence of CKD (defined by
ICD-9 criteria) before AKI found that after a median follow-
up of 2.3 years, an AKI event was associated with a twofold
increased risk of death. Adjustment for post-discharge eGFR
only modestly attenuated the risk estimate.18 Bihorac et al.21
identified a long-term, 20% increased (adjusted) risk of
death after AKI among postoperative patients without kidney
disease before surgery; this risk was similar for the sub-
population with renal recovery, although recovery was
defined liberally as a post-AKI serum creatinine level up to
50% higher than baseline. We suspect that the difference in
definition of recovery explains the discrepancy in mortality
risk between this study and the results we report. Our study
findings are not inconsistent with those of Wald et al.,22 who
found no association between AKI and the long-term risk of
death among those who required renal replacement therapy
for AKI but recovered sufficient function to discontinue
therapy within 30 days. As the cohort definition, AKI severity,
and classification of recovery were quite different in this
analysis compared with ours, caution is advised in drawing
comparisons between the two analyses. The findings we
report would suggest that any long-term mortality risk
among patients with recovered AKI is largely influenced
by the subsequent development of CKD rather than the
AKI event itself.
CKD, when it developed, occurred relatively early after
hospital discharge in this cohort. Whether this represents the
natural history of AKI as it pertains to the development of
subsequent CKD, or to limitations of estimating recovery
from AKI based on serum creatinine-based criteria23 (e.g., an
overestimation of true GFR by serum creatinine-based
criteria influenced by volume status or other factors), is not
clear. Others have reported on the subsequent development
of advanced CKD after AKI. Lo et al.24 reported on the
development of stage 4 or 5 CKD among those with baseline
GFR above 45 ml/min who suffered dialysis-requiring AKI
Table 6 | Predictors of de novo CKD by Cox proportional
hazard analysis among propensity score–matched patients
experiencing AKI (n=1610)
Covariate HR (95% CI) P-value
Age, per year 1.01 (1.01, 1.02) 0.0004
Baseline eGFR, per ml/min increase 0.97 (0.96, 0.97) o0.0001
Charlson Co-morbidity Index Score
1 vs. 0 1.38 (1.15, 1.66) 0.0006
2+ vs. 0 1.46 (1.22, 1.75) o0.0001
Echocardiogram during 12 months
before index admission date
1.14 (0.98, 1.32) 0.09
Serum albumin test ordered during
12 months before index admission date
4.27 (2.38, 7.67) o0.0001
Baseline outpatient serum albumin,
per 1.0 g/dl increase
0.74 (0.64, 0.85) o0.0001
CHF 1.28 (1.03, 1.60) 0.03
Hypertension 1.28 (1.10, 1.51) 0.002
AKI stagea
2 vs. 1 1.78 (1.52, 2.09) o0.0001
3 vs. 1 1.58 (1.23, 2.05) 0.0003
Hospital LOS, per day 1.00 (1.00, 1.01) 0.02
Abbreviations: AKI, hospital-acquired acute kidney injury; CHF, congestive heart
failure; eGFR, estimated glomerular filtration rate; LOS, length of stay.
aHA-AKI stage (1, 2, or 3) was defined by the peak increase in serum creatinine
during the hospitalization relative to baseline (X150 too200%,X200 too300% or
X300% or requiring renal replacement therapy, respectively).
482 Kidney International (2012) 81, 477–485
or ig ina l a r t i c l e ID Bucaloiu et al.: Death and CKD after reversible AKI
but recovered sufficient function to discontinue treatment
within 30 days. Relative to controls, those exposed were 28
times more likely to develop advanced CKD in adjusted
models. As in our analysis, the outcome developed soon after
discharge in a large proportion of exposed patients.
We also identified risk factors for the subsequent develop-
ment of CKD among survivors of AKI. Among previously
reported risk factors for CKD, such as hypertension, older age,
and congestive heart failure, stage of AKI (using the Acute
Kidney Injury Network staging criteria) and a physician’s
order for measurement of serum albumin within the prior
12 months predicted longitudinal CKD development. These
factors are quite similar to those recently reported by Chawla
et al.,25 and we agree with their supposition that identifying
at-risk patients at the time of hospital discharge using these
commonly available characteristics may allow for the timely
implementation of appropriate screening and surveillance.
Potential limitations of this study should be considered.
Because of the observational nature of our study, we cannot
exclude the possibility that unmeasured factors related to
both the exposure and outcomes resulted in biased estimates
of the impact of AKI. However, to limit the potential for both
confounding and bias, we used propensity score matching
across a broad set of demographic and clinical characteristics
to establish the study cohort. In addition, our study
population—from a single integrated health-care system in
Central Pennsylvania—is not necessarily representative of
hospitalized populations in the US or elsewhere, and the
results should therefore be interpreted within that context.
The matching process, as expected, resulted in a final cohort
that includes those AKI cases with relatively mild underlying
disease burden and lower severity of acute illness relative to
the AKI cases that did not successfully match; care should
therefore be taken when extrapolating these study findings.
Finally, the analyses are based on non-protocolized sampling
of lab values included in the modeling for this community-
based cohort; although we accounted for the absence of
these specific lab tests using validated statistical methods,
the potential for indication bias may have influenced the
study results.
In summary, reversible episodes of AKI in patients
without preexisting kidney disease have important prognostic
value. If confirmed in other populations, given the large
absolute numbers of hospitalized patients experiencing AKI
worldwide, the impact and utility of management strategies
for primary CKD prevention among those patients without
preexisting CKD who experience AKI would warrant further
investigation.
MATERIALS AND METHODS
This project was approved by the Geisinger Institutional Review Board
on 9 February 2010. The study data source was Geisinger’s electronic
health record, EpicCare, which contains detailed demographic,
procedural, laboratory, radiographic, vital, and other clinical data
for more than 3.5 million patients receiving care at Geisinger Health
System, an integrated health-care system in Central Pennsylvania.26
Design and participants
A propensity score–matched cohort was developed. First, we
identified all adults (18–88 years) who were discharged from
Geisinger Medical Center between 1 January 2004 and 31 December
2007, and who were alive 90 days after discharge. The index
hospitalization was the first hospitalization after 1 January 2004
during which AKI occurred for the exposed group, and the first
hospitalization after 1 January 2004 for patients without evidence of
AKI throughout the entire study period. We excluded all patients
with one or more eGFR values below 60 ml/min per 1.73 m2 in the
year before index admission, all patients with hematuria (‘trace’
blood or greater by semiquantitative dipstick analysis), proteinuria
(semiquantitative dipstick analysis result of 30 mg/dl or greater, a
urinary protein-to-creatinine ratio greater than 0.2 mg protein per g
creatinine, or a 24-h urine collection with at least 300 mg protein),
microalbuminuria (defined as a random urine albumin-to-
creatinine ratio greater than 30 mg per g creatinine, or a 24-h urine
albumin above 30 mg), or any of the following procedures or
conditions documented in the medical record during the year
preceding the index hospitalization: renal replacement therapy
(any prior hemodialysis or peritoneal dialysis; Current Procedural
Terminology (CPT) 90935, 90937, 90945, 90947, 90960–90962,
90966, 90970, or ICD-9-CM 585.5 or 585.6), history of autosomal
dominant polycystic kidney disease (ICD-9-CM 753.12 or 753.13),
unilateral nephrectomy (CPT 50300, 50320, 50323, 50325,
50327–50329 or ICD-9-CM 593.83), or any solid-organ or bone
marrow transplant. Patients discharged from the hospital within 30
days before the index admission and women who had any
pregnancy-related diagnosis within 90 days before or 90 days after
the index hospitalization were also excluded.
We calculated patient-specific propensity scores for an episode
of AKI using a non-parsimonious, binary logistic regression
method.27–29 We considered the 12 months before the index hospitali-
zation for comorbid conditions (defined by the presence of an ICD-9-
CM diagnosis for a given condition associated with at least two distinct
outpatient encounters, or listed on the medical problem list),
procedures and surgeries (using CPT codes), and major infections;
and 6 months prior for medications (using electronic prescription
records). Factors present during the hospitalization itself (length of stay,
requirement for critical care services, and serum albumin level closest
and before discharge date) were also included. Specifically, we assessed
demographic characteristics; smoking status (‘ever’ vs. ‘never’); the
Charlson Co-morbidity Index;30 comorbid conditions such as diabetes,
hypertension, coronary artery disease, congestive heart failure, cardiac
dysrhythmia, peripheral vascular disease, cancer, dementia, chronic
liver disease (chronic hepatitis, alcoholic fatty liver, hepatorenal
syndrome, portosystemic encephalopathy, spontaneous bacterial peri-
tonitis, esophageal varices), COPD, asthma, and obesity; major
infections (sepsis and septicemia, intra-abdominal infections, CNS
infections, acute and subacute endocarditis, community acquired,
nosocomial, bacterial, fungal, and viral pneumonias, pyelonephritis and
perinephric abscess, and skin and soft tissue infections); laboratory tests
(baseline eGFR as described below, serum albumin within 3 months
before the hospital admission; cardiovascular testing (electrocardio-
gram, echocardiogram, cardiac stress testing) and procedures (coronary
angiography); cardiovascular surgical interventions (coronary, carotid,
aortic, or other peripheral arterial revascularization); and a prescription
for one or more medications associated with renal or cardiovascular
disease. A detailed list of ICD-9-CM and CPT codes, and medications,
along with operational definitions for all variables, is available in
Supplementary Appendix online.
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Exposure
The study exposure was AKI, defined as a 50% increase relative
to baseline occurring during hospitalization.18,31,32 Baseline serum
creatinine was defined as the lowest value recorded between
3 months before the index admission date and 30 days after the
hospital discharge date. In patients without a serum creatinine
measurement within 90 days preceding the hospitalization, the lowest
value between the index admission date and 30 days after discharge
was used to define baseline kidney function.32 ‘Recovery’ of renal
function was defined as an eGFR value within at least 90% of baseline
eGFR occurring within 90 days of AKI. All GFR values were estimated
using the CKD Epidemiology Collaboration (CKD-EPI) creatinine
equation,33 based on serum creatinine values measured using the
isotope dilution/mass spectroscopy traceable Roche enzymatic
method.34 Baseline eGFR was the value derived from this formula
using the baseline serum creatinine, as defined above. Two sensitivity
analyses were performed whereby those cases defined using a baseline
serum creatinine occurring within the 90-day pre-AKI window, and
those occurring within the 30-day post-AKI window, were analyzed
separately in an adjusted Cox proportional hazard model.
Subjects were followed up from the date of recovery eGFR
(if experiencing AKI) or date of index hospital discharge (if not
experiencing AKI) until death or the end of the study period
(31 December 2009).
Outcomes
The primary study outcome was death. Vital status is coded in the
Geisinger database as a distinct data field, and is updated monthly
using the Social Security Administration’s data set through the
National Technical Information Service.35 The secondary outcome
was the development of CKD, defined as the occurrence of two or
more eGFR valuesp59 ml/min per 1.73 m2, separated in time by at
least 90 but no more than 365 days. The date of first occurrence was
then considered the onset of de novo CKD.
Statistical methods
For the purposes of baseline comparison, all qualifying patients were
stratified by the presence or absence of AKI during the index
hospitalization. Continuous variables were assessed for deviations
against a normal distribution using Quantile–Quantile plots.
Data are presented as mean and standard deviation for normally
distributed, continuous variables, median and interquartile range for
non-normally distributed variables, and as frequency and percentages
for categorical variables. Comparisons between groups were made
using the Wilcoxon nonparametric and Pearson’s w2 tests. For each
individual patient, a propensity score for the development of AKI was
estimated using logistic regression, treating development of AKI as the
outcome. Patient demographic and clinical characteristics thought to
influence either exposure status or outcomes were selected for
inclusion in the model (Supplementary Appendix online). Individuals
experiencing AKI were matched with up to three controls using a
5-1 digit ‘greedy’ match algorithm.36 Post-matching comparisons
between groups were made using the standardized difference, a
technique that is independent of the sample size.37 A standardized
difference o10 was considered an acceptable balance between
groups.37 Incident rates for mortality and CKD were expressed as
the number of events per 1000 person years. The Poisson regression
model was used to estimate and compare the incidence rates, and
presented as incidence rate ratios with corresponding 95% CI. Crude
survival was estimated for those with AKI and controls using the
Kaplan–Meier method.
Death and CKD were then each analyzed in a time-to-event
manner, using a Cox proportional hazard regression model with a
robust sandwich estimate of the variance to account for the inherent
correlation due to the matching process. Results are expressed as
HRs and corresponding 95% CIs. Post-matching variables with
a standardized difference between matched groups greater than
10 were adjusted for in the multivariate Cox proportional hazards
model. In addition, because of the association of CKD with death, we
added de novo CKD as a time-dependent covariate to the Cox model.
Subgroup analyses were performed based on age, diabetic status,
receipt of critical care services during the index hospitalization,
and Charlson Co-morbidity Index Score. These subgroup analyses
were similarly adjusted for both imbalanced baseline covariates
and CKD developing during follow-up. Variability of the group
effect was assessed using interactions between subgroups of interest
and the group indicator within the Cox proportional hazard
regression model.
For outpatient and inpatient serum albumin levels, because more
than 10% of the cohort did not have a test order for these
parameters, we created a dummy variable to indicate whether or not
the test was ordered, and included these dummy variables in the
univariate and adjusted models, as appropriate.38
Because of the effect of matching on cohort size and the potential
bias introduced by loss of cases, an additional sensitivity analysis was
performed whereby the unmatched cohort was used in a multi-
variable Cox proportional hazard regression model to determine the
association between AKI and long-term mortality. Covariates used
in this sensitivity analysis included all variables used in propensity
score matching, as well as in the development of CKD during
follow-up, in time-dependent manner.
Finally, because of the strong association of subsequent CKD
development and mortality risk among survivors of AKI, a Cox
proportional hazard regression model was developed to identify
factors present at the time of index hospitalization among those
experiencing AKI, which independently predicted subsequent CKD
development. For this analysis, the same variables used to compare the
AKI and control groups at baseline were used as potential predictors
of de novo CKD. Those specific variables that were significant at
Pp0.10 in the univariate analysis were entered into the Cox model
and sequentially eliminated using a backward stepwise approach.
Analyses were performed using SAS 9.2 (SAS Institute Inc,
Cary, NC).
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